title: Nonsteroidal anti-inflammatory drug or glucosamine reduced pain and improved muscle strength with resistance training in a randomized controlled trial of knee osteoarthritis patients.
abstract: OBJECTIVE
  To investigate the effect of 12 weeks of strength training in combination with a nonsteroidal anti-inflammatory drug (NSAID), glucosamine, or placebo on muscle cross-sectional area (CSA), strength (primary outcome parameters), and function, power, pain, and satellite cell number (secondary outcome parameters) in patients with knee osteoarthritis (OA).
  
  
  METHODS
  Double-blinded, randomized controlled trial.
  
  
  METHODS
  Hospital.
  
  
  METHODS
  Patients (N=36; 20 women, 16 men; age range, 50-70y) with bilateral tibiofemoral knee OA. A total of 181 patients were approached, and 145 were excluded.
  
  
  METHODS
  Patients were randomly assigned to treatment with the NSAID ibuprofen (n=12), glucosamine (n=12), or placebo (n=12) during 12 weeks of quadriceps muscle strength training.
  
  
  METHODS
  Muscle CSA and strength.
  
  
  RESULTS
  No differences between groups were observed in gains in muscle CSA. Training combined with ibuprofen increased maximal isometric strength by an additional .22Nm/kg (95% confidence interval [CI], .01-.42; P=.04), maximal eccentric muscle strength by .38Nm/kg (95% CI, .05-.70; P=.02), and eccentric muscle work by .27J/kg (95% CI, .01-.53; P=.04) in comparison with placebo. Training combined with glucosamine increased maximal concentric muscle work by an additional .24J/kg versus placebo (95% CI, .06-.42; P=.01).
  
  
  CONCLUSIONS
  In patients with knee OA, NSAID or glucosamine administration during a 12-week strength-training program did not improve muscle mass gain, but improved maximal muscle strength gain in comparison with treatment with placebo. However, we do not find that the benefits are large enough to justify taking NSAIDs or glucosamine.
authors.affiliation: Institute of Sports Medicine, Department of Orthopaedic Surgery M, Bispebjerg Hospital and Centre for Healthy Ageing, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark. susannegp@gmail.com.dk
authors.forename: Susanne G
authors.initials: SG
authors.lastname: Petersen
authors.forename: Nina
authors.initials: N
authors.lastname: Beyer
authors.forename: Mette
authors.initials: M
authors.lastname: Hansen
authors.forename: Lars
authors.initials: L
authors.lastname: Holm
authors.forename: Per
authors.initials: P
authors.lastname: Aagaard
authors.forename: Abigail L
authors.initials: AL
authors.lastname: Mackey
authors.forename: Michael
authors.initials: M
authors.lastname: Kjaer
mesh_terms: D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005944:Glucosamine / Q000627:therapeutic use*; D006801:Humans; D007052:Ibuprofen / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D053580:Muscle Strength / Q000187:drug effects* / Q000502:physiology*; D020370:Osteoarthritis, Knee / Q000188:drug therapy* / Q000503:physiopathology / Q000534:rehabilitation*; D010146:Pain / Q000188:drug therapy* / Q000534:rehabilitation*; D010147:Pain Measurement; D010919:Placebos; D055070:Resistance Training; D032496:Satellite Cells, Skeletal Muscle / Q000187:drug effects / Q000502:physiology; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D010919:Placebos; D005944:Glucosamine; D007052:Ibuprofen